Here’s What Analysts Think About Arcus Biosciences (RCUS)

Arcus Biosciences, Inc. (NYSE:RCUS) is 1 of the champion immunotherapy stocks to bargain according to hedge funds. On February 12, Arcus Biosciences, Inc. (NYSE:RCUS) was downgraded to Equal Weight from Overweight astatine Wells Fargo, with the steadfast bringing the terms people connected the banal down to $23 from $30. The steadfast attributed the downgrade to unclear differentiation for Welireg and the imaginable information readout headwinds from the American Society of Clinical Oncology Genitourinary Cancers Symposium. It further told investors successful a probe enactment that the LITESPARK-001 and 002 readouts astatine ASCO-GU evaluating Welireg positive Keytruda whitethorn airs a antagonistic interaction connected the shares of Arcus Biosciences, Inc. (NYSE:RCUS) and Exelixis.

In different development, Bank of America Securities reiterated a Hold standing connected Arcus Biosciences, Inc. (NYSE:RCUS) connected January 15, mounting a terms people of $26. However, Goldman Sachs assumed sum and upgraded the banal to Buy from Neutral connected January 12, adjusting the terms people to $28 from $16.

The steadfast highlighted casdatifan, the company’s pb asset, arsenic a potent and selective HIF-2alpha inhibitor nether improvement for precocious wide compartment renal compartment carcinoma with a full addressable marketplace of astir 17.4K patients successful the US/EU and astir $1.7B estimated successful risk-adjusted highest sales. Goldman Sachs stated that the company’s Phase 1 ARC-20 results successful second-line exhibited notable wide effect ratios of 31% and 46% for the mono and combo regimen, respectively, and whitethorn amusement further betterment with the combo proceedings maturing past the 5-month follow-up.

Arcus Biosciences, Inc. (NYSE:RCUS) is simply a clinical-stage biopharmaceutical institution that develops and commercializes immunotherapies. The institution competes successful segments specified arsenic biotechnology, pharmaceutical, and different related sectors that make immunotherapies for crab treatment.

While we admit the imaginable of RCUS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.